Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast
The multiple myeloma therapy market continues to grow, fueled by the disease’s increasing incidence and the long treatment duration. The availability of premium-priced branded agents prescribed in multidrug regimens, particularly Darzalex-based therapies, is impacting the disease’s treatment algorithm. Although Bristol Myers Squibb’s Revlimid and Janssen / Takeda Pharmaceutical’s Velcade remain the cornerstones of treatment, recently approved novel therapies such as CAR T-cell therapies (Bristol Myers Squibb / Bluebird Bio’s Abecma and Janssen’s Carvykti) and bispecific antibodies (Janssen’s Tecvayli and Talvey, and Pfizer’s Elrexfio) have expanded the number of options available. Emerging therapies—Venclexta / Venclyxto and next-generation IMiDs iberdomide and mezigdomide—will compete fiercely. Nevertheless, clinical and commercial potential remains for therapies with improved efficacy and therapies able to treat underserved patient populations, such as those with smoldering multiple myeloma.
Questions answered
- What is the size of the drug-treatable multiple myeloma population, and how do drug-treatment rates vary by geography, line of therapy, and over time?
- How will the use of Revlimid and Velcade change over the forecast period, and what impact will generic entry have on the market?
- How will physicians manage the treatment sequencing of BCMA-targeted therapies such as CAR T cells, antibody-drug conjugates, and bispecific antibodies?
- What are thought leaders’ opinions of therapies in late-stage development, such as the bispecific antibody cevostamab, the apoptosis-inducing agent Venclexta / Venclyxto, and the CELMoDs iberdomide and mezigdomide?
- What are the drivers of, and constraints on, the therapy market?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan
Primary research: 18 country-specific interviews with thought-leading hematologist-oncologists supported by survey data collected for this and other Clarivate research
Epidemiology: Incidence of multiple myeloma by country, segmented by line of therapy and symptomatic status
Emerging therapies: Phase 3: 5 drugs; coverage of select Phase 1 and 2 products
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Major-market share of drug classes for multiple myeloma: 2022
- Major-market share of drug classes for multiple myeloma: 2032
- Drug-treatable population share and major-market sales share in multiple myeloma: 2022
- Drug-treatable population share and major-market sales share in multiple myeloma: 2032
- Population positioning of current therapies in multiple myeloma
- Population positioning of emerging therapies in multiple myeloma
- Multiple myeloma SWOT analysis
- Market drivers and constraints
- Segment-specific trends
- Smoldering multiple myeloma
- First-line transplant-eligible multiple myeloma
- Patient-share dynamics of key regimens in first-line transplant-eligible multiple myeloma in the United States: 2022-2032
- First-line transplant-ineligible multiple myeloma
- Patient-share dynamics of key regimens in first-line transplant-ineligible multiple myeloma in the United States: 2022-2032
- Relapsed / refractory multiple myeloma
- Patient-share dynamics of key regimens in second-line multiple myeloma in the United States: 2022-2032
- Patient-share dynamics of key regimens in third-line multiple myeloma in the United States: 2022-2032
- Patient-share dynamics of key regimens in fourth-line multiple myeloma in the United States: 2022-2032
- Patient-share dynamics of key regimens in fifth- to seventh-line multiple myeloma in the United States: 2022-2032
- Key findings
- Forecast
- Etiology and Pathophysiology
- Disease overview
- Disease pathophysiology
- Risk factors
- Staging and classification
- Key pathways and drug targets
- Drug targets and potential therapies for multiple myeloma
- IMiD-mediated disruption of myeloma cell-microenvironment interactions
- Potentially synergistic antitumor effects of proteasome and aggresome pathways
- Biology of selective inhibitors of nuclear export (SINE)
- Biology of B-cell maturation antigen (BCMA)
- Aminopeptidases in apoptosis of myeloma cells
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for multiple myeloma
- Current treatments used for multiple myeloma
- Market events impacting the use of key current therapies in multiple myeloma
- Cell-surface-targeted agents
- Immunomodulatory agents
- Proteasome inhibitors
- CAR T-cell therapies
- Selective inhibitors of nuclear export
- Antibody-drug conjugates
- Bispecific therapies
- Apoptosis-inducing agents
- Histone deacetylase inhibitors
- Medical practice
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Louis Perdios, M.Chem., M.Res., Ph.D., Manager, Healthcare Research & Data Analytics, Oncology. Dr. Perdios oversees a team of analysts who produce syndicated primary and secondary market research reports containing disease-specific insights. He has many years of experience in pharmaceutical analytics and has worked in multiple therapy areas on market forecasting, market research, branding, and life-cycle management projects. Previously, he worked at Airfinity as a lead healthcare analyst, specializing in hematological malignancies. Dr. Perdios also held senior analyst positions in oncology at GlobalData and IQVIA. He completed his Ph.D. in structural biology at Imperial College London, in collaboration with UCL and AstraZeneca, and holds an M.Res. in drug discovery and development from Imperial College London. He also holds a master’s degree in medicinal chemistry from the University of Newcastle upon Tyne.
Joan Tur, M.Sc., Ph.D., Healthcare Research & Data Analyst, Oncology. Dr. Tur conducts market research and forecasting in a range of oncology indications. He has several years of experience as a pharmaceutical industry analyst with the Cortellis Competitive Intelligence group, serving as the team’s immuno-oncology expert. Prior to joining Clarivate, Dr. Tur was a researcher in inflammation and macrophage biology at the Barcelona Science Park. He holds a Ph.D. in biomedicine, an M.Sc. in immunology, and a B.Sc. in biology from the University of Barcelona.